SynthesisAnticancer research2018
Postoperative Hypofractionated Radiation Therapy in Prostate Carcinoma: A Systematic Review.
Synthesis in Anticancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Moderate hypofractionation: long-term toxicity results of prostate bed radiotherapy (FRAME-PROSTATE).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Long-term Outcomes of Toxicities and Disease Control Following Postoperative Moderately Hypofractionated Radiotherapy in High-Risk Prostate Cancer: Results of a Prospective Study.Clinical and translational radiation oncology · 2026Article
- Hydraulic endorectal actuator for prostate radiotherapy reduces variations in motion in a silicone rectal phantom.Frontiers in oncology · 2026Article
- Unraveling the safety of adjuvant radiotherapy in prostate cancer: impact of older age and hypofractionated regimens on acute and late toxicity - a multicenter comprehensive analysis.Frontiers in oncology · 2023Article
- Acute Toxicity and Quality of Life in a Post-Prostatectomy Ablative Radiation Therapy (POPART) Multicentric Trial.Current oncology (Toronto, Ont.) · 2022Observational
- Article
- Hypofractionated Postoperative Radiotherapy for Prostate Cancer: Is the Field Ready Yet?European urology open science · 2020Review
- Multiparametric MRI for prostate cancer: a national survey of patterns of practice among radiation oncologists in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Article
- Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes.Cancer management and research · 2018Article
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimA systematic review on toxicity, local control (LC), overall survival (OS), and biochemical relapse-free survival (bRFS) after postoperative hypofractionated radiotherapy (HFRT) on prostate cancer (PCa) was performed. MATERIALS AND
methodsBased on the PRISMA methodology, studies reporting clinical results after adjuvant or salvage HFRT were included.
resultsA total of 1,208 patients from 17 eligible studies were included. Median follow-up was 30 months. No case of severe acute gastrointestinal (GI) toxicity was recorded. Grade ≥3 acute genitourinary (GU) toxicity ranged between 0% and 3%. Different rates of grade ≥2 late GI (range=0-8.7%) and GU (range=0-66%) toxicity were recorded. Encouraging results on LC, OS, and bRFS were reported.
conclusionAcute toxicity does not seem to be increased in patients receiving postoperative HFRT, but the results of late-GU toxicity are conflicting. Further prospective studies are needed before including postoperative HFRT in clinical practice.
Indexed as
Identifiers
29491044What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.